Drugs marked with (*) are high risk drugs;#percentage of total prescriptions in this group causing an ADR.†most often prescribed drugs (n>25),††NA = not applicable as it is one-sided, 97.5% CI.
The FEARS datasets include adverse drug events for mulitpe periods( 2004Q1-2011Q4 ). The FDA released the datasets publicly. More information can be seen in the website of FDA:https://open.fda.gov/dat
Gemcitabine is widely used in the treatment of various cancers. This study aims to evaluate gemcitabine-associated adverse events (AEs) using the Food and Drug Administration Adverse Event Reporting S
Ongoing studies are evaluating the efficacy and toxicity profiles of combining epidermal growth factor receptor inhibitors (EGFR-TKIs) with antiangiogenic agents in non-small cell lung cancer (NSCLC).
